Market Overview:
The global infliximab and biosimilar market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologic therapies, and growing number of product approvals. The infliximab and biosimilar market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into infliximab, infliximab-dyyb (Inflectra), and infliximab-abcda (Renflexis). The Crohn's disease segment accounted for the largest share of this market in 2017.
Product Definition:
Infliximab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α) and blocks its interaction with the TNF receptor. Infliximab is used to treat autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis. It is also used to treat severe plaque psoriasis.
A biosimilar is a biological product that is highly similar to another already approved biologic product. The term "biosimilar" was first introduced in 2005 in the European Union (EU) as part of legislation known as Directive 2004/27/EC on pharmacovigilance of medicinal products for human use. The directive defined a biosimilar as: "a biological medicinal product which contains a version of the active substance of an already authorised original biological medicinal product.
Infliximab:
Infliximab is a drug that reduces the immune response to any antigen (body protein), which helps in the treatment of rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. It works by decreasing cytokines (chemical signals) that are responsible for inflammation. The drug was approved by Health Canada in 2003 and was first sold in Canada under the brand name Injexa.
Infliximab-dyyb:
Infliximab-dyyb is an interleukin-6 antibody. It works by binding to the interleukin-6 receptor, which in turn blocks the signal from cytokines that are involved in inflammation. The drug was approved by the FDA for treatment of Crohn's disease and ulcerative colitis patients on December 28, 2007.
Application Insights:
The Crohn's disease segment dominated the global infliximab and biosimilar market in terms of revenue share in 2017. This is due to the increasing prevalence of this condition which has resulted in growing demand for therapeutics that can manage symptoms such as abdominal pain, diarrhea, and fatigue. In addition, new product launches are expected to contribute toward market growth during the forecast period. For instance, on January 31st 2018 Teva Pharmaceuticals launched Inflectra for treatment of moderately-to-severely active Crohn's disease. The company claims that its drug is 97% effective based on results from clinical trials involving 685 patients with moderate-to-severely active UC or CD who were not able to respond adequately to other therapies.
The plaque psoriasis segment is expected to exhibit lucrative growth over the forecast period owing to factors such as rising awareness about causes leading a person develop psoriasis along with increased spending capacity among consumers especially in Europe.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. In addition, favorable insurance policies are also anticipated to boost revenue growth in this region.
Asia Pacific is expected to be the fastest-growing regional segment over the forecast period owing to an increase in healthcare expenditure by governments and private agencies as well as rising awareness about new treatment options for chronic diseases such as Infximab & biosimilars. Moreover, growing disposable income levels will also contribute towards market growth during this period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the infliximab and biosimilar market. According to a study by the World Health Organization (WHO), over 350 million people are affected by autoimmune diseases worldwide, and this number is expected to increase in the coming years. This will create a high demand for infliximab and biosimilars as they are used to treat various autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ulcerative colitis.
- Rising healthcare expenditure: The rising healthcare expenditure is another major growth driver for the infliximab and biosimilar market. According to a study by MarketsandMarkets, the global healthcare expenditure is expected to reach trillion by 2020. This will create a high demand for expensive drugs such as infliximab and its biosimilars as they offer better treatment outcomes than traditional therapies.
- Technological advancements: The technological advancements in drug discovery and development are another key growth driver for the infliximab and biosimilar market . Over the past few years, there has been an increase in R&D investments in this area which has led to significant advances in biotechnology tools that can be used for manufacturing complex therapeutics such as monoclonal antibodies (mAbs). This has helped reduce production costs of these drugs which is likely to result in their increased adoption
Scope Of The Report
Report Attributes
Report Details
Report Title
Infliximab and Biosimilar Market Research Report
By Type
Infliximab, Infliximab-dyyb, Infliximab-abda
By Application
Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
By Companies
Janssen Biotech, Merck and Co., Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Infliximab and Biosimilar Market Report Segments:
The global Infliximab and Biosimilar market is segmented on the basis of:
Types
Infliximab, Infliximab-dyyb, Infliximab-abda
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Janssen Biotech
- Merck and Co.
- Pfizer
Highlights of The Infliximab and Biosimilar Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Infliximab
- Infliximab-dyyb
- Infliximab-abda
- By Application:
- Crohn's Disease
- Pediatric Crohn's Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Infliximab and Biosimilar Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Infliximab is a monoclonal antibody used to treat rheumatoid arthritis. It is also known by the trade name Remicade. Biosimilar refers to a drug that is similar to an existing medication, but has been developed using biotechnology instead of traditional pharmaceutical manufacturing methods.
Some of the major companies in the infliximab and biosimilar market are Janssen Biotech, Merck and Co., Pfizer.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Infliximab and Biosimilar Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Infliximab and Biosimilar Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Infliximab and Biosimilar Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Infliximab and Biosimilar Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Infliximab and Biosimilar Market Size & Forecast, 2018-2028
4.5.1 Infliximab and Biosimilar Market Size and Y-o-Y Growth
4.5.2 Infliximab and Biosimilar Market Absolute $ Opportunity
Chapter 5 Global Infliximab and Biosimilar Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Infliximab and Biosimilar Market Size Forecast by Type
5.2.1 Infliximab
5.2.2 Infliximab-dyyb
5.2.3 Infliximab-abda
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Infliximab and Biosimilar Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Infliximab and Biosimilar Market Size Forecast by Applications
6.2.1 Crohn's Disease
6.2.2 Pediatric Crohn's Disease
6.2.3 Ulcerative Colitis
6.2.4 Rheumatoid Arthritis
6.2.5 Ankylosing Spondylitis
6.2.6 Psoriatic Arthritis
6.2.7 Plaque Psoriasis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Infliximab and Biosimilar Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Infliximab and Biosimilar Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Infliximab and Biosimilar Analysis and Forecast
9.1 Introduction
9.2 North America Infliximab and Biosimilar Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Infliximab and Biosimilar Market Size Forecast by Type
9.6.1 Infliximab
9.6.2 Infliximab-dyyb
9.6.3 Infliximab-abda
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Infliximab and Biosimilar Market Size Forecast by Applications
9.10.1 Crohn's Disease
9.10.2 Pediatric Crohn's Disease
9.10.3 Ulcerative Colitis
9.10.4 Rheumatoid Arthritis
9.10.5 Ankylosing Spondylitis
9.10.6 Psoriatic Arthritis
9.10.7 Plaque Psoriasis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Infliximab and Biosimilar Analysis and Forecast
10.1 Introduction
10.2 Europe Infliximab and Biosimilar Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Infliximab and Biosimilar Market Size Forecast by Type
10.6.1 Infliximab
10.6.2 Infliximab-dyyb
10.6.3 Infliximab-abda
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Infliximab and Biosimilar Market Size Forecast by Applications
10.10.1 Crohn's Disease
10.10.2 Pediatric Crohn's Disease
10.10.3 Ulcerative Colitis
10.10.4 Rheumatoid Arthritis
10.10.5 Ankylosing Spondylitis
10.10.6 Psoriatic Arthritis
10.10.7 Plaque Psoriasis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Infliximab and Biosimilar Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Infliximab and Biosimilar Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Infliximab and Biosimilar Market Size Forecast by Type
11.6.1 Infliximab
11.6.2 Infliximab-dyyb
11.6.3 Infliximab-abda
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Infliximab and Biosimilar Market Size Forecast by Applications
11.10.1 Crohn's Disease
11.10.2 Pediatric Crohn's Disease
11.10.3 Ulcerative Colitis
11.10.4 Rheumatoid Arthritis
11.10.5 Ankylosing Spondylitis
11.10.6 Psoriatic Arthritis
11.10.7 Plaque Psoriasis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Infliximab and Biosimilar Analysis and Forecast
12.1 Introduction
12.2 Latin America Infliximab and Biosimilar Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Infliximab and Biosimilar Market Size Forecast by Type
12.6.1 Infliximab
12.6.2 Infliximab-dyyb
12.6.3 Infliximab-abda
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Infliximab and Biosimilar Market Size Forecast by Applications
12.10.1 Crohn's Disease
12.10.2 Pediatric Crohn's Disease
12.10.3 Ulcerative Colitis
12.10.4 Rheumatoid Arthritis
12.10.5 Ankylosing Spondylitis
12.10.6 Psoriatic Arthritis
12.10.7 Plaque Psoriasis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Infliximab and Biosimilar Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Infliximab and Biosimilar Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Infliximab and Biosimilar Market Size Forecast by Type
13.6.1 Infliximab
13.6.2 Infliximab-dyyb
13.6.3 Infliximab-abda
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Infliximab and Biosimilar Market Size Forecast by Applications
13.10.1 Crohn's Disease
13.10.2 Pediatric Crohn's Disease
13.10.3 Ulcerative Colitis
13.10.4 Rheumatoid Arthritis
13.10.5 Ankylosing Spondylitis
13.10.6 Psoriatic Arthritis
13.10.7 Plaque Psoriasis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Infliximab and Biosimilar Market: Competitive Dashboard
14.2 Global Infliximab and Biosimilar Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Janssen Biotech
14.3.2 Merck and Co.
14.3.3 Pfizer
